bluebird bio, Inc. (BLUE)
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
$75.74M
Mr. Andrew Obenshain
518.00
Cambridge, MA
Jun 19, 2013
-0.17
$-2.30
0.48
0.68
-567.29%
-0.25
0.00
1.48
1.43
0.57
-57.13%
-207.25%
Similar stocks (7)
Madrigal Pharmaceuticals, Inc.
MDGL
Krystal Biotech, Inc.
KRYS
PTC Therapeutics, Inc.
PTCT
Agios Pharmaceuticals, Inc.
AGIO
Mersana Therapeutics, Inc.
MRSN
Karyopharm Therapeutics Inc.
KPTI
Hepion Pharmaceuticals, Inc.
HEPA
ETF Exposure (14)
Loncar Cancer Immunotherapy ETF
CNCR
3.28%
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.34%
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
0.08%
iShares Micro-Cap ETF
IWC
0.01737%
iShares Biotechnology ETF
IBB
0.00708%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.007%
iShares Russell 2000 Value ETF
IWN
0.00549%
iShares Russell 2000 ETF
IWM
0.0027%
ProShares Ultra Nasdaq Biotechnology
BIB
0.0022312776047842963%
ProShares Hedge Replication ETF
HDG
4.186681061567723e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.8459000000000004e-4%
Dimensional U.S. Equity ETF
DFUS
4.1469999999999994e-5%
iShares Russell 3000 ETF
IWV
4.0e-5%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
0%
Similar stocks (7)
Madrigal Pharmaceuticals, Inc.
MDGL
Krystal Biotech, Inc.
KRYS
PTC Therapeutics, Inc.
PTCT
Agios Pharmaceuticals, Inc.
AGIO
Mersana Therapeutics, Inc.
MRSN
Karyopharm Therapeutics Inc.
KPTI
Hepion Pharmaceuticals, Inc.
HEPA
ETF Exposure (14)
Loncar Cancer Immunotherapy ETF
CNCR
3.28%
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.34%
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
0.08%
iShares Micro-Cap ETF
IWC
0.01737%
iShares Biotechnology ETF
IBB
0.00708%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.007%
iShares Russell 2000 Value ETF
IWN
0.00549%
iShares Russell 2000 ETF
IWM
0.0027%
ProShares Ultra Nasdaq Biotechnology
BIB
0.0022312776047842963%
ProShares Hedge Replication ETF
HDG
4.186681061567723e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.8459000000000004e-4%
Dimensional U.S. Equity ETF
DFUS
4.1469999999999994e-5%
iShares Russell 3000 ETF
IWV
4.0e-5%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
0%